Case Closed On PFO Closure? A Principal Investigator Weighs In
This article was originally published in The Gray Sheet
Executive Summary
Future prospects for devices that close patent foramen ovale heart defects to prevent recurrent strokes remain in some doubt as researchers continue to mull recent data.
You may also be interested in...
Advisors Provide Lukewarm Endorsement Of St. Jude's PFO Occluder For Stroke
FDA's Circulatory System Devices Panel said that St. Jude's Amplatzer PFO closure device has benefits that outweigh risks to prevent recurrent stroke in a select group of patients on an 11-5 vote, despite having missed its primary endpoint in the pivotal RESPECT trial.
St. Jude Hopes Its PFO Occluder Gets RESPECT At May FDA Panel
St. Jude won a May panel date for its Amplatzer patent foreman ovale occluder PMA, seeking approval to prevent recurrent stroke. It's been a challenging path to this point after the firm's pivotal RESPECT trial did not meet its primary endpoint in 2012.
Research In Brief
Research reports on PFO closure, mid-urethral slings, telehealth and more.